Technology's new home can be found in "Silicon Slopes," Utah.
European shares recovered slightly Tuesday to close narrowly lower, as worrying euro zone signals gave way to better-than-expected U.S. factory orders.
Oct 9- Fresenius Medical Care AG& Co KGaA:. *Moody's assigns baa3 rating to Fresenius Medical care's proposed senior. *Rpt-moody's assigns baa3 rating to fresenius medical care's proposed.
European companies that export their goods are sure bets for investing, two fund managers told CNBC Thursday.
Click here for 4 potential winners and 5 possible losers if the euro falls a whole lot more!
It appears weakness in Europe might not be an equal opportunity albatross. In fact, some may find the situation somewhat welcoming.
What follows is a roundup of corporate earnings reports for Wednesday, Feb. 24.
Last year investors just had to buy the "cheapest, nastiest stocks" around and watch them rally in the "dash to trash," but this year requires a more measured approach, Karen Olney, strategist from UBS, told CNBC Monday.
Germany’s economy is the third largest in the world in terms of GDP, after the United States and Japan, with a $3.3 trillion GDP in 2007. Here are stats and stocks from Germany.
America lost an important civil servant -- a hero of the masses -- when Bob Steele gave up his post of Treasury Undersecretary to take over the reins of the troubled Wachovia Bank spacer. Cramer worked with him at Goldman Sachs spacer and praises him simply a "brilliant man," not a compliment Cramer gives often -- with the exception of certain dead classical composers. Steele is a "visionary and a hard worker," someone who "gets" that the banking system is in dire straits.
Cramer last week offered up his prediction of potential winners from the new Medicare bill -- the one that passed in the Senate yesterday. (President Bush has said he'll veto -- but it already passed by a veto-proof margin.) The good news is that Fresenius Med (FMS), Cramer's fave of the bill, got bumped to a 52-week high today with three points. But what about the losers of the Medicare bill -- the new offenders headed for the Sell Block?
German health care group Fresenius plans to buy APP Pharmaceuticals in a $3.7 billion deal to expand into the North American intravenous generic drugs market.
Wall Street overlooks Washington all the time. And that's your opportunity.
Allscripts could see tremendous growth when a new Medicare bill is passed.
Fresenius might cash in once the new bill passes.
Some lucky companies will split up $454 billion this year. But who?